Nemolizumab: A Comprehensive Profile of a First-in-Class IL-31 Receptor Alpha Antagonist

I. Introduction to Nemolizumab

A. Identification and Classification

Nemolizumab, identified by DrugBank ID DB15252 and Chemical Abstracts Service (CAS) number 1476039-58-3, is a novel biologic therapy developed for chronic inflammatory and pruritic skin conditions.[1] It is classified as a biotech product, specifically a humanized Immunoglobulin G2 (IgG2) monoclonal antibody (mAb).[1] The selection of the IgG2 isotype for nemolizumab is noteworthy; compared to IgG1 antibodies often used in oncology, IgG2 antibodies generally exhibit reduced effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This characteristic may represent a deliberate design choice to enhance the safety profile in the context of chronic inflammatory diseases, where the therapeutic goal is primarily modulation of signaling pathways rather than depletion of receptor-bearing cells.[1]

Nemolizumab functions as a highly specific Interleukin-31 Receptor alpha (IL-31RA) antagonist.[1] It is marketed under the brand name Nemluvio® in the United States (US), European Union (EU), United Kingdom (UK), and Switzerland, and as Mitchga® in Japan.[1] Other identifiers used during its development include CIM-331 and the nonproprietary name suffix nemolizumab-ilto.[2]

As a monoclonal antibody, nemolizumab is a large protein molecule with an approximate average molecular weight of 144 kDa.[1] Detailed amino acid sequence information for its constituent heavy and light chains is publicly available.[3]

B. Development and Commercialization History

Nemolizumab was originated and invented by Chugai Pharmaceutical Co., Ltd., a Japanese pharmaceutical company.[2] Its creation utilized Chugai's proprietary antibody engineering technology, ACT-Ig, which may contribute to extending the antibody's biological half-life.[44]

In 2016, Chugai established strategic licensing agreements to facilitate the global development and commercialization of nemolizumab [2]:

1. Galderma S.A. acquired exclusive rights for the development and marketing of nemolizumab worldwide, with the exceptions of Japan and Taiwan.
2. Maruho Co., Ltd., a company specializing in dermatology within Japan, obtained the rights for the development and marketing of nemolizumab specifically for skin diseases in the Japanese market. Chugai Pharmaceutical retained responsibility for the manufacturing and supply of the product.[44]

This tripartite structure, involving the originator (Chugai), a global partner (Galderma), and a regional specialist (Maruho), exemplifies a common strategy in the pharmaceutical industry. It allows for leveraging specialized local expertise, particularly important in markets with unique regulatory landscapes and clinical practices like Japan's dermatology sector, while simultaneously utilizing a partner with established global infrastructure for broader market access.[41] This approach has led to distinct regional branding (Nemluvio® globally, Mitchga® in Japan) and tailored regulatory submissions and approvals based on regional studies and requirements.[30]

II. Mechanism of Action: Targeting the IL-31 Pathway

A. The Role of Interleukin-31 (IL-31) and its Receptor (IL-31RA/OSMRβ)

Interleukin-31 (IL-31) has emerged as a pivotal cytokine in the pathophysiology of chronic pruritic and inflammatory dermatoses, particularly atopic dermatitis (AD) and prurigo nodularis (PN).[1] It is classified as a neuroimmune cytokine, reflecting its capacity to bridge signaling between the nervous and immune systems.[16] IL-31 is predominantly produced by T helper type 2 (Th2) cells, but also by other immune cells (monocytes, macrophages, eosinophils, basophils, dendritic cells) and resident skin cells like keratinocytes and fibroblasts.[15] Elevated levels of IL-31 or its receptor have been documented in the serum or lesional tissue of patients with these conditions.[23]

IL-31 exerts its biological effects by binding to a heterodimeric receptor complex composed of the IL-31 Receptor alpha (IL-31RA) subunit and the Oncostatin M Receptor beta (OSMRβ) subunit.[15] This receptor complex is expressed on various cell types relevant to skin pathology, including sensory neurons, keratinocytes, and immune cells.[15] Binding of IL-31 initiates intracellular signaling cascades, primarily through the Janus kinase/signal transducer and activator of transcription (JAK/STAT), phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT), and mitogen-activated protein kinase (MAPK) pathways.[9]

The downstream consequences of IL-31 signaling are multifaceted and directly contribute to the clinical features of AD and PN:

• Pruritus (Itch): IL-31 is a potent pruritogen. It directly activates sensory nerve endings in the skin and dorsal root ganglia, transmitting itch signals to the central nervous system and contributing to the intense, often debilitating, pruritus characteristic of these diseases.[1] It also promotes sensory nerve growth, potentially leading to hypersensitivity.[16]
• Inflammation: IL-31 contributes to skin inflammation, involving both Th2 and non-Th2 pathways, and promotes the release of other pro-inflammatory cytokines and chemokines.[1]
• Skin Barrier Dysfunction: IL-31 signaling can impair skin barrier integrity, for instance, by downregulating the expression of key structural proteins like filaggrin and claudin-1 in keratinocytes. This exacerbates dryness and increases susceptibility to environmental triggers.[14]
• Fibrosis: IL-31 is implicated in tissue remodeling and fibrosis, a process particularly relevant to the formation of the characteristic hardened nodules in PN.[1]

B. Nemolizumab as an IL-31 Receptor Alpha (IL-31RA) Antagonist

Nemolizumab employs a targeted mechanism of action by functioning as a selective antagonist of the IL-31RA subunit.[1] It binds with high affinity and specificity to IL-31RA, thereby physically preventing the cytokine IL-31 from engaging with its receptor complex.[1] This blockade inhibits the recruitment of the OSMRβ co-receptor and prevents the formation of the active signaling complex, effectively silencing downstream intracellular signal transduction pathways (JAK/STAT, PI3K/AKT, MAPK) that are normally triggered by IL-31.[1]

Targeting the receptor (IL-31RA) directly, rather than scavenging the ligand (IL-31), provides a potentially robust and comprehensive blockade of the pathway, irrespective of fluctuations in IL-31 levels or its diverse cellular sources.[1] This specific receptor antagonism is central to nemolizumab's therapeutic effect.

C. Neuroimmune Modulation and Downstream Effects

The antagonism of IL-31RA by nemolizumab leads to significant modulation of the neuroimmune interactions driving AD and PN. By inhibiting IL-31 signaling, nemolizumab effectively reduces the release and activity of downstream pro-inflammatory mediators.[1] Crucially, it disrupts the itch-scratch cycle by directly attenuating the IL-31-mediated stimulation of sensory neurons responsible for pruritus.[15] This direct impact on the nervous system component, alongside its effects on immune cells and keratinocytes, justifies its description as a neuroimmune response modulator.[1]

Furthermore, the blockade addresses other key pathological features driven by IL-31, including cutaneous inflammation, compromised skin barrier function, and the fibrotic tissue remodeling prominent in PN.[1] The ability to impact multiple facets of these complex diseases—itch, inflammation, barrier integrity, and fibrosis—through the targeted inhibition of a single receptor pathway provides a strong rationale for nemolizumab's therapeutic efficacy across both AD and PN, despite their distinct clinical presentations.

III. Clinical Development and Efficacy

A. Overview of Major Clinical Trial Programs

The clinical development of nemolizumab has been anchored by two major Phase III programs:

• OLYMPIA (OLYMPIA 1 and OLYMPIA 2): These trials investigated nemolizumab as monotherapy for moderate-to-severe Prurigo Nodularis (PN) in adults.[2] The OLYMPIA program represents the largest clinical trial initiative completed for PN to date.[26]
• ARCADIA (ARCADIA 1 and ARCADIA 2): These identical trials evaluated nemolizumab as an add-on therapy to background topical treatments (corticosteroids with or without calcineurin inhibitors) for moderate-to-severe Atopic Dermatitis (AD) in adolescents (aged ≥12 years) and adults.[4]

Both programs involved large, global, randomized, double-blind, placebo-controlled designs, providing high-level evidence for regulatory submissions.[2] These pivotal trials were preceded by Phase II studies that established proof-of-concept and informed dose selection, including trials like NCT03100344 and NCT01986933 for AD [64] and earlier Phase II work in PN.[47]

B. Efficacy in Prurigo Nodularis (PN)

The OLYMPIA 1 and OLYMPIA 2 trials enrolled adults with moderate-to-severe PN, defined by criteria including a minimum number of nodules (≥20), significant disease severity (Investigator's Global Assessment [IGA] score ≥3), and severe pruritus (weekly average Peak Pruritus Numeric Rating Scale score ≥7).[58] Participants were randomized 2:1 to receive subcutaneous nemolizumab or placebo every 4 weeks (Q4W).[58]

Primary Efficacy Endpoints (at Week 16): Both trials successfully met their co-primary endpoints, demonstrating statistically significant and clinically meaningful improvements with nemolizumab compared to placebo.[26]

• Itch Response: Defined as achieving a ≥4-point improvement from baseline in the weekly average PP-NRS score. In OLYMPIA 1, 58.4% of nemolizumab patients achieved this response versus 16.7% of placebo patients (Δ 40.1%, P <.001). In OLYMPIA 2, the rates were 56% versus 21% (P <.0001).[35] An alternative analysis using the Worst Itch NRS (WI-NRS) in a meta-analysis also showed a significant benefit (Risk Ratio 3.52, P < 0.00001).[57]
• Skin Lesion Clearance (IGA Success): Defined as achieving an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline. In OLYMPIA 1, 26.3% of nemolizumab patients achieved IGA success versus 7.3% of placebo patients (Δ 14.6%, P =.003). In OLYMPIA 2, the rates were 38% versus 11% (P <.0001).[35] A meta-analysis confirmed this benefit (Risk Ratio 4.40, P < 0.00001).[57]

Key Secondary Endpoints: Nemolizumab also demonstrated superiority over placebo for all key secondary endpoints in the OLYMPIA trials.[26]

• Rapid Onset of Action: Significant itch relief (≥4-point PP-NRS reduction) was observed as early as Day 3 in post-hoc analyses [62] and was statistically significant versus placebo by Week 4 in the primary trial analyses (e.g., OLYMPIA 1: 41.1% vs 6.3%, P <.0001).[24] This rapid effect on pruritus is a hallmark finding, consistent with the drug's mechanism targeting the primary itch cytokine IL-31.
• Sleep Disturbance: Patients treated with nemolizumab experienced significant improvements in sleep quality, measured by the Sleep Disturbance NRS (SD-NRS). Significant differences versus placebo were seen by Day 4 [62], and at Week 16, approximately 50-52% of nemolizumab patients achieved a clinically meaningful ≥4-point reduction in SD-NRS compared to 12-21% in the placebo groups (P <.001).[26] This highlights the substantial impact of itch reduction on overall quality of life.

Long-Term Efficacy and Durability: Data from the OLYMPIA Long-Term Extension (LTE) study provided evidence of sustained and potentially increasing efficacy with continued treatment.[52] An interim analysis at Week 52 showed:

• Over 80% of patients continuously treated with nemolizumab maintained or achieved a ≥4-point PP-NRS itch response.
• Over 60% achieved IGA 0/1 (clear/almost clear skin).
• Improvements in sleep disturbance (SD-NRS) and quality of life (Dermatology Life Quality Index, DLQI) also continued to improve.[52]
• Patients naïve to nemolizumab who entered the LTE experienced rapid itch reduction, similar to those initially randomized to the drug.[52] Furthermore, a randomized withdrawal study demonstrated durability of response. Patients responding at Week 52 who continued nemolizumab had a significantly lower relapse rate (17%) over the subsequent 24 weeks compared to those withdrawn to placebo (75%).[50] This suggests that continuous therapy is likely necessary for maintaining control in PN. The continued improvement in skin lesions over the longer term (beyond 16 weeks) may reflect the time required for tissue remodeling and resolution of fibrotic nodules after the persistent itch-scratch cycle has been interrupted.

C. Efficacy in Atopic Dermatitis (AD)

The ARCADIA 1 and ARCADIA 2 trials assessed nemolizumab 30 mg SC Q4W (following a 60 mg loading dose) added to background topical therapies (TCS +/- TCI) in adolescents (≥12 years) and adults with moderate-to-severe AD inadequately controlled by topicals alone.[4]

Co-Primary Efficacy Endpoints (at Week 16): Both trials met their co-primary endpoints, demonstrating the superiority of nemolizumab plus topicals over placebo plus topicals.[24]

• IGA Success (Score 0/1 and ≥2-grade improvement): In ARCADIA 1, 36% of the nemolizumab group achieved IGA success versus 25% of the placebo group (P=0.0003). In ARCADIA 2, the rates were 38% versus 26% (P=0.0008).[14]
• EASI-75 Response (≥75% improvement in Eczema Area and Severity Index): In ARCADIA 1, 44% of the nemolizumab group achieved EASI-75 versus 29% of the placebo group (P<0.0001). In ARCADIA 2, the rates were 42% versus 30% (P=0.0011).[14]

Key Secondary Endpoints: All key secondary endpoints were also met, further supporting nemolizumab's efficacy.[24]

• Itch Response (≥4-point PP-NRS reduction): At Week 16, significantly more patients in the nemolizumab groups achieved this endpoint (ARCADIA 1: 48.6% vs 20.5%; ARCADIA 2: 48.1% vs 20.6%; P<0.0001 for both).[24]
• Rapid Itch Relief: Similar to the PN trials, nemolizumab demonstrated a rapid onset of action on itch, with significant improvements versus placebo observed as early as Day 1 or Day 2 in post-hoc analyses [65] and by Week 1 in the primary analyses.[14] This again highlights the direct impact on IL-31 mediated pruritus.
• Sleep Disturbance: Significant improvements in sleep disturbance (measured by SD-NRS) were observed by Week 16 compared to placebo.[14]

Long-Term Efficacy and Maintenance: The ARCADIA LTE study provided insights into long-term outcomes and maintenance dosing.[51]

• Sustained Response: The majority of patients who responded at Week 16 maintained their skin (IGA, EASI-75) and itch (PP-NRS) responses through to Week 48.[52]
• Continued Improvement: Clinically meaningful improvements in skin lesions, itch, sleep, and QoL continued to increase over time up to Week 56.[50] For instance, at Week 56, approximately 47-49% achieved IGA 0/1, and 73-79% achieved EASI-75, representing further improvement from Week 16 levels.[53] Itch (SCORAD VAS) and Sleep Loss (SCORAD VAS) improved by ~70-75% from lead-in baseline by Week 56.[51]
• Maintenance Dosing: Similar efficacy was observed for both Q4W and Q8W maintenance dosing regimens among Week 16 responders, suggesting that less frequent dosing may be feasible for maintaining response in some patients.[52]

D. Findings in Specific Populations (Adolescents - NCT03921411)

The dedicated Phase II trial NCT03921411 specifically evaluated nemolizumab in adolescents (aged 12-17 years) with moderate-to-severe AD.[66] This open-label, 16-week study used a 60 mg loading dose followed by 30 mg Q4W, alongside background topical therapies.

• Efficacy: Marked improvements were observed by Week 16: mean EASI score decreased by 66.5%, mean PP-NRS score decreased by 43.2%, and mean sleep disturbance NRS score decreased by 53.5%.[67]
• Pharmacokinetics/Pharmacodynamics (PK/PD): Population PK modeling indicated a similar PK profile (adjusted for body weight) and exposure-response relationship for EASI, IGA, and PP-NRS endpoints in these adolescents compared to adults receiving the same dosing regimen.[67] This finding supported the inclusion of adolescents in the Phase III ARCADIA program and the subsequent regulatory approvals down to age 12.

E. Biomarker Data and Correlation with Clinical Response

Biomarker analyses have provided molecular evidence corroborating nemolizumab's mechanism of action and clinical effects.

• Skin Biomarkers (Adolescent AD Study - NCT03921411): Analysis of stratum corneum tape strips revealed that several pro-inflammatory biomarkers associated with AD pathogenesis (e.g., CCL20, CCL22, CCL27, VEGF) were upregulated in lesional skin compared to non-lesional skin at baseline. Following nemolizumab treatment, these biomarkers were significantly downregulated in patients who achieved a clinical response (defined by EASI-75 or ≥4-point PP-NRS improvement). The magnitude of downregulation was greater in EASI responders.[67] This indicates that nemolizumab treatment reverses key inflammatory signatures in the skin of responders.
• Skin Biomarkers (ARCADIA - EADV 2024): Transcriptomic analysis using tape strips from ARCADIA participants showed that nemolizumab treatment significantly modulated gene expression related to pruritus, inflammation (including Th2 and Th17 pathways), and skin barrier function. These molecular changes correlated with clinical improvements. Notably, patients with more severe baseline itch exhibited a more robust reduction in these biomarkers following treatment, suggesting a strong link between IL-31 pathway activity, biomarker expression, and clinical phenotype.[50]

These biomarker studies provide valuable mechanistic validation, demonstrating that nemolizumab's clinical efficacy is associated with modulation of the targeted IL-31 pathway and its downstream effects on inflammation and skin barrier function at the tissue level.

Table 1: Summary of Key Phase III Efficacy Outcomes (OLYMPIA & ARCADIA at Week 16)

Endpoint	Trial	Nemolizumab Group (%)	Placebo Group (%)	Treatment Difference (%) [95% CI] / P-value	Reference(s)
Prurigo Nodularis (OLYMPIA)
≥4-point PP-NRS Improvement	OLYMPIA 1	58.4	16.7	40.1 [29.4–50.8] (P <.001)	58
	OLYMPIA 2	56.3	20.9	35.4 [24.9–45.9] (P <.001)	35
IGA Success (0/1 & ≥2-grade improvement)	OLYMPIA 1	26.3	7.3	14.6 [6.7–22.6] (P =.003)	58
	OLYMPIA 2	37.7	11.0	26.7 [16.7–36.7] (P <.001)	35
Atopic Dermatitis (ARCADIA)
IGA Success (0/1 & ≥2-grade improvement)	ARCADIA 1	35.6	24.6	11.5 [4.7–18.3] (P =.0003)	35
	ARCADIA 2	37.7	26.0	11.8 [4.6–19.1] (P =.0008)	35
EASI-75 Response	ARCADIA 1	43.5	29.0	14.6 [7.7–21.5] (P <.0001)	35
	ARCADIA 2	42.1	30.2	11.9 [4.4–19.4] (P =.0011)	35

Abbreviations: AD=Atopic Dermatitis; CI=Confidence Interval; EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; PN=Prurigo Nodularis; PP-NRS=Peak Pruritus Numeric Rating Scale.

Note: ARCADIA results are for nemolizumab + background topicals vs. placebo + background topicals. OLYMPIA results are for nemolizumab monotherapy vs. placebo.

IV. Pharmacokinetics and Administration

A. Pharmacokinetic Profile

Nemolizumab exhibits pharmacokinetic (PK) properties typical of a humanized IgG2 monoclonal antibody following subcutaneous administration.

• Absorption: After subcutaneous (SC) injection, nemolizumab is absorbed slowly into the systemic circulation. Studies have shown that drug exposure, measured as area under the concentration-time curve (AUC) and maximum concentration (Cmax), increases in an approximately dose-proportional manner following both single SC doses (ranging from 0.03 to 3 mg/kg) and multiple SC doses (up to 30 mg).[1]
• Distribution: Specific details on the volume of distribution were not found in the reviewed materials. However, as a large protein molecule (~144 kDa), nemolizumab's distribution is expected to be primarily confined to the vascular and interstitial compartments, with limited penetration into tissues, consistent with other mAbs.[1]
• Metabolism: Like other therapeutic proteins, nemolizumab is expected to be metabolized through general protein catabolism pathways, broken down into smaller peptides and amino acids by proteolytic enzymes throughout the body.[2] It is not anticipated to be metabolized by the cytochrome P450 (CYP450) enzyme system, which is the primary route for small molecule drug metabolism. This lack of CYP450 involvement significantly reduces the potential for typical pharmacokinetic drug-drug interactions (DDIs) mediated by these enzymes. A clinical study (NCT04562116) was conducted to assess the effects of nemolizumab on CYP substrates in AD patients, likely evaluating potential indirect effects on enzyme activity via cytokine modulation, but results were not available in the reviewed snippets.[68]
• Elimination: Nemolizumab exhibits a long terminal elimination half-life (t1/2), estimated at approximately 18.9 days (standard deviation 4.96 days).[1] This extended half-life is characteristic of IgG antibodies and is a key factor enabling infrequent dosing.
• Clearance: The estimated systemic clearance (CL) of nemolizumab is approximately 0.263 L/day.[1]

B. Factors Influencing Pharmacokinetics

Clinical studies have identified body weight as a significant factor influencing nemolizumab pharmacokinetics.

• Body Weight: In the adolescent AD study (NCT03921411), body weight was identified as the main source of PK variability.[67] This observation provides a rationale for the weight-tiered dosing strategy employed in the OLYMPIA trials and subsequently approved for the PN indication in adults (<90 kg vs. ≥90 kg receiving different maintenance doses).[2] The use of a fixed dose for the AD indication across adolescents and adults, despite weight variability, suggests that the exposure achieved with the fixed dose falls within an acceptable therapeutic window for this condition, or that the exposure-response relationship is relatively flat within the resulting exposure range.
• Age: PK parameters and exposure-response profiles were found to be similar between adolescents (12-17 years) and adults when receiving the same dosing regimens, indicating that age within this range does not significantly impact nemolizumab's PK.[67] PK data in younger children (e.g., 6-11 years, studied in NCT04921345 [69]) were not detailed in the reviewed sources but informed the specific pediatric approvals in Japan.[40]

C. Dosage Regimen and Route of Administration

Nemolizumab is administered via subcutaneous (SC) injection.[1] The long elimination half-life supports a convenient dosing frequency, typically once every 4 weeks (Q4W), starting from the initial dose.[2] This Q4W schedule is noted as a potential advantage for patient adherence compared to biologics requiring more frequent administration.[20]

A loading dose is administered at baseline (Week 0) to rapidly achieve therapeutic concentrations.[2] Approved maintenance dosages vary by indication and region:

• Atopic Dermatitis (US/EU/UK/Swiss; ≥12 years): 60 mg loading dose, followed by 30 mg Q4W maintenance dose, used in combination with topical therapies.[31] Long-term extension data from ARCADIA suggest that an Q8W maintenance schedule might be feasible for patients who respond well initially, although this is not currently reflected in the primary approved dosing.[52]
• Prurigo Nodularis (US/EU/UK/Swiss; Adults): 60 mg loading dose. Maintenance dose is weight-based: patients <90 kg receive 30 mg Q4W, while patients ≥90 kg receive 60 mg Q4W.[2]
• Japan (Mitchga®):
• AD-associated Pruritus (≥13 years): 60 mg Q4W via pre-filled syringe.[30]
• AD-associated Pruritus (6 to <13 years): 30 mg Q4W via vial.[40]
• Prurigo Nodularis (≥13 years): 60 mg loading dose, followed by 30 mg Q4W via vial.[40]

Nemolizumab is supplied in various presentations depending on the market, including single-dose pre-filled pens (containing lyophilized powder and diluent for reconstitution prior to administration in the US), pre-filled syringes, and vials.[26]

V. Safety and Tolerability Profile

A. Overview of Safety Data from Clinical Trials

Across the Phase III clinical trial programs (OLYMPIA and ARCADIA) and subsequent long-term extension (LTE) studies, nemolizumab has demonstrated a generally favorable safety and tolerability profile.[14] In the pivotal 16-week placebo-controlled periods, the overall incidence and types of adverse events (AEs) were generally similar between the nemolizumab and placebo groups (when both were combined with background topical therapies in the ARCADIA AD trials).[28] The majority of reported AEs were mild or moderate in severity.[58] Importantly, long-term treatment data extending up to 52 or 56 weeks did not reveal any new or unexpected safety signals, supporting the potential for chronic use.[50]

B. Common Adverse Events Reported in PN and AD Trials

The most frequently reported adverse reactions (incidence ≥1%) observed in the clinical trials varied slightly depending on the indication:

Table 2: Common Adverse Events (≥1% Incidence) by Indication

Adverse Reaction	Prurigo Nodularis (PN)	Atopic Dermatitis (AD)	Reference(s)
Headache (including migraine)	✓	✓	16
Skin Rashes (Atopic dermatitis, Eczema, Eczema nummular)	✓		16
Arthralgia (Joint pain)		✓	16
Urticaria (Hives)		✓	16
Myalgia (Muscle aches)		✓	16

Other commonly reported AEs across various studies included nasopharyngitis, upper respiratory tract infections, and gastrointestinal symptoms (e.g., abdominal pain, diarrhea).[14] Peripheral edema and exacerbation of existing AD or eczema were also noted in some studies.[14] The reporting of AD or eczema as a common AE specifically in the PN trials is an interesting observation. While PN and AD can co-exist, this finding might suggest either diagnostic overlap in the trial populations or potentially a drug-related effect linked to immune modulation in individuals predisposed to eczematous reactions.

C. Serious Adverse Events and Warnings/Precautions

Serious adverse events (SAEs) were reported infrequently in the clinical trials.[14] SAEs considered possibly related to nemolizumab occurred in a small percentage of participants (e.g., ~1% in ARCADIA 2).[56]

Key warnings and precautions associated with nemolizumab use include:

• Hypersensitivity Reactions: Nemolizumab is contraindicated in patients with a known hypersensitivity to the active substance or any of its excipients. Serious hypersensitivity reactions are possible. Patients should be advised to seek immediate medical attention if symptoms such as breathing difficulties, wheezing, swelling of the face/lips/mouth/tongue/throat, fainting, dizziness, rapid pulse, swollen lymph nodes, joint pain, fever, or rash occur.[16]
• Vaccinations: Patients should not receive live vaccines immediately before or during treatment with nemolizumab.[22] The potential impact on the response to non-live vaccines has also been studied (NCT04365387) [66], though results were not detailed in the provided snippets.
• Pregnancy and Breastfeeding: There are no adequate and well-controlled studies of nemolizumab in pregnant women. Its use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. It is unknown whether nemolizumab is excreted in human breast milk or if it can harm a nursing infant. Caution is advised when administering to breastfeeding mothers.[10] Due to its large molecular size, significant transfer into milk and subsequent infant absorption is considered unlikely, but data are lacking.[10]

While the overall safety profile is favorable, rare case reports have emerged suggesting the potential for paradoxical immune-mediated cutaneous adverse events, such as psoriasiform eruptions or bullous pemphigoid, following nemolizumab treatment.[73] The proposed mechanism involves potential shifts in immune balance (e.g., suppression of Th2 leading to compensatory Th17 activation) secondary to IL-31 pathway inhibition. Although infrequent, these reports warrant clinical vigilance for unexpected inflammatory skin reactions during therapy.

VI. Regulatory Status and Global Approvals

A. Approvals by Major Regulatory Agencies

Nemolizumab has achieved regulatory approval in several major global markets for the treatment of PN and/or AD:

• United States (FDA): Nemluvio® was approved for adults with prurigo nodularis on August 13, 2024.[1] Subsequently, it was approved for moderate-to-severe atopic dermatitis in patients aged 12 years and older (in combination with topical therapies) on December 13, 2024.[2] The FDA considers nemolizumab a first-in-class medication.[2]
• European Union (EMA/European Commission): Nemluvio® received marketing authorization for both moderate-to-severe atopic dermatitis (patients ≥12 years who are candidates for systemic therapy) and moderate-to-severe prurigo nodularis (adults who are candidates for systemic therapy) on February 14, 2025.[2] This followed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued on December 12, 2024.[2]
• Japan (MHLW): Mitchga® received its first global approval on March 28, 2022, for the treatment of pruritus associated with atopic dermatitis in adults and children aged 13 years and older (when existing treatment is insufficiently effective).[1] On March 26, 2024, approvals were expanded to include pruritus associated with AD in children aged 6 to <13 years (using a 30mg vial formulation) and prurigo nodularis in patients aged 13 years and older.[40]
• United Kingdom (MHRA) & Switzerland (Swissmedic): Nemluvio® was granted marketing authorization via the Access Consortium framework for both moderate-to-severe AD (≥12 years, ≥30kg, with topicals) and moderate-to-severe PN (adults) on February 18, 2025.[37]

Regulatory reviews are ongoing in other regions, including Australia, Singapore, Canada, and Brazil, partly through collaborative frameworks like the Access Consortium.[31] The rapid succession of approvals across these key markets highlights the perceived clinical value and the strength of the supporting data from the Phase III programs.

B. Approved Indications and Patient Populations (Summary)

The approved indications reflect the positive outcomes from the OLYMPIA and ARCADIA trials:

• Prurigo Nodularis (PN): Generally approved for adults with moderate-to-severe disease.[1] The age range extends down to ≥13 years in Japan.[40]
• Atopic Dermatitis (AD): Approved for moderate-to-severe AD in patients aged 12 years and older in the US, EU, UK, and Switzerland, typically specified as being candidates for systemic therapy or having inadequate response to topicals, and used in combination with topical treatments.[2]
• Atopic Dermatitis-associated Pruritus (Japan): Approved specifically for itch associated with AD in patients (≥6 years) with insufficient response to existing therapies, with different age cutoffs for the 60mg syringe (≥13 years) and 30mg vial (6 to <13 years) formulations.[1]

The variations in exact wording, age ranges, and combination therapy requirements across regions likely stem from differences in the specific clinical data packages submitted, regional regulatory standards, and the evolution of clinical evidence during the global development timeline.

C. Key Regulatory Designations

Nemolizumab received important designations from the US FDA that facilitated its development and review, particularly for the PN indication:

• Breakthrough Therapy Designation: Granted in December 2019 for the treatment of pruritus associated with prurigo nodularis.[2] This designation is intended for drugs treating serious conditions where preliminary clinical evidence suggests substantial improvement over available therapies.
• Priority Review: Granted in February 2024 for the prurigo nodularis indication.[26] This designation expedites the FDA review process for drugs that could offer significant improvements in safety or effectiveness for serious conditions.

The granting of both designations underscores the recognition by the FDA of the significant unmet medical need in PN and the potential of nemolizumab, based on early clinical data, to provide a meaningful therapeutic advance.

VII. Conclusion and Future Perspectives

A. Summary of Nemolizumab's Therapeutic Profile

Nemolizumab (Nemluvio®/Mitchga®) represents a significant advancement in the treatment of chronic pruritic and inflammatory skin diseases. As a first-in-class, humanized IgG2 monoclonal antibody targeting the IL-31 receptor alpha (IL-31RA), it offers a novel and specific mechanism of action by blocking the signaling of the neuroimmune cytokine IL-31. Clinical evidence from large, well-controlled Phase III trials (OLYMPIA for PN, ARCADIA for AD) has robustly demonstrated its efficacy. Key benefits include:

• Rapid and Significant Itch Relief: A hallmark effect observed in both PN and AD, often within days or weeks of treatment initiation.
• Improvement in Skin Lesions: Significant reduction in the severity and extent of skin manifestations (nodules in PN, eczematous lesions in AD).
• Enhanced Quality of Life: Marked improvements in sleep disturbance, a major consequence of chronic itch.
• Favorable Safety Profile: Generally well tolerated in clinical trials up to at least one year, with a safety profile consistent with other biologics used in dermatology.
• Convenient Dosing: A subcutaneous injection administered once every four weeks provides a patient-friendly regimen.

B. Clinical Significance as a First-in-Class IL-31RA Inhibitor

The development and approval of nemolizumab mark the clinical validation of the IL-31 pathway as a critical therapeutic target in dermatology. Its unique mechanism, focusing on the neuroimmune axis by inhibiting IL-31RA, distinguishes it from therapies targeting other inflammatory cytokines (like IL-4, IL-13, IL-17, IL-23) or broader pathways (like JAK inhibitors). It is specifically positioned as a potent anti-pruritic agent, directly addressing the most burdensome symptom for many patients with AD and PN, with consequent improvements in inflammation and skin lesions. This targeted approach represents a paradigm shift, particularly for PN, which previously lacked specifically approved, effective therapies.

C. Potential Role in Dermatology Practice and Unmet Needs Addressed

Nemolizumab is poised to fill significant unmet needs in the management of moderate-to-severe AD and PN. Its rapid onset of itch relief is a particularly compelling attribute for patients suffering from intense, debilitating pruritus that significantly impairs sleep and overall quality of life. It offers a valuable new option for:

• Adults with moderate-to-severe PN, providing the first targeted biologic therapy for this challenging condition.
• Adolescents (≥12 years) and adults with moderate-to-severe AD, especially those whose condition is dominated by severe itch or who have had inadequate responses to other systemic therapies or topical treatments. It serves as an important addition to the growing armamentarium of biologics for AD, offering a distinct mechanism focused on itch.

The Q4W dosing schedule enhances convenience and potentially improves long-term adherence.

D. Ongoing Research and Potential Future Indications

While nemolizumab has secured approvals for AD and PN in major markets, research continues. Long-term extension studies from the OLYMPIA and ARCADIA programs are yielding valuable data on the durability of response and safety with prolonged use.[50] These studies will help refine understanding of optimal long-term management, including the potential viability of less frequent maintenance dosing (e.g., Q8W) for some AD patients.[52]

The successful validation of the IL-31 pathway in AD and PN naturally raises interest in nemolizumab's potential utility in other conditions where IL-31-mediated itch is implicated. Clinical investigation has occurred in chronic kidney disease-associated pruritus (CKDaP) and systemic sclerosis (SSc), with a Phase II trial in SSc (NCT05214794) reported as completed.[29] Further studies in these or other pruritic conditions may expand nemolizumab's therapeutic reach. Additionally, expanding the approved indications to younger pediatric populations (<12 years for AD outside Japan, <18 years for PN) will likely require dedicated clinical trials.[16]

In conclusion, nemolizumab stands as a pioneering therapy targeting the IL-31 pathway. Its demonstrated ability to rapidly and effectively control itch, improve skin lesions, and enhance quality of life in patients with moderate-to-severe atopic dermatitis and prurigo nodularis, coupled with a favorable safety profile and convenient dosing, establishes it as a significant therapeutic innovation in dermatology.

Works cited

1. Nemolizumab: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed April 30, 2025, https://go.drugbank.com/drugs/DB15252
2. Nemolizumab - Wikipedia, accessed April 30, 2025, https://en.wikipedia.org/wiki/Nemolizumab
3. Nemolizumab - Inxight Drugs, accessed April 30, 2025, https://drugs.ncats.io/substance/GN465U8B72
4. Nemolizumab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/drug/dcc0d512ad4b4fcea93ebce7f25d9568
5. Nemolizumab | Interleukin - TargetMol, accessed April 30, 2025, https://www.targetmol.com/compound/nemolizumab
6. Nemolizumab (CIM331) | CAS 1476039-58-3 - AbMole BioScience, accessed April 30, 2025, https://www.abmole.com/products/nemolizumab.html
7. Nemolizumab | 1476039-58-3 - ChemicalBook, accessed April 30, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB68080930.htm
8. Nemolizumab (Anti-IL-31Ra) IL Receptor antibody | Read Reviews & Product Use Citations, accessed April 30, 2025, https://www.selleckchem.com/products/nemolizumab-anti-il-31ra.html
9. Human IL-31R (IL-31RA) Antibody - Nemolizumab Biosimilar - InvivoGen, accessed April 30, 2025, https://www.invivogen.com/anti-human-il-31r-nemolizumab-biosimilar-antibody
10. Nemolizumab - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed April 30, 2025, https://www.ncbi.nlm.nih.gov/books/n/lactmed/nemolizumab/
11. Nemolizumab (CIM331) | IL-31 Inhibitor - MedchemExpress.com, accessed April 30, 2025, https://www.medchemexpress.com/nemolizumab.html
12. Nemolizumab|Cas# 1476039-58-3 - GlpBio, accessed April 30, 2025, https://www.glpbio.com/nemolizumab.html
13. NEMOLIZUMAB - GSRS, accessed April 30, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/GN465U8B72
14. Nemolizumab is the First IL-31 Inhibitor for Atopic Dermatitis - MedCentral, accessed April 30, 2025, https://www.medcentral.com/dermatology/atopic-dermatitis/nemolizumab-in-line-to-be-the-first-il-31-inhibitor-for-atopic-dermatitis
15. Blockage of the IL-31 Pathway as a Potential Target Therapy for ..., accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9961325/
16. NEMLUVIO® (nemolizumab-ilto) Mechanism of Action for AD, accessed April 30, 2025, https://www.nemluviohcp.com/atopic-dermatitis/discover-nemluvio/moa
17. Nemolizumab: Uses, Benefits and Side-effects - DermNet, accessed April 30, 2025, https://dermnetnz.org/topics/nemolizumab
18. FDA Approves Nemolizumab: First IL-31 Blocker for the Treatment of Prurigo Nodularis, accessed April 30, 2025, https://www.nycallergydoctor.com/blog/fda-approves-nemolizumab-first-il-31-blocker-for-the-treatment-of-prurigo-nodularis
19. What is the mechanism of action of Nemolizumab? - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-nemolizumab
20. Christophe Piketty, MD, PhD: Nemolizumab's Unique Mechanism of Action and Next Steps Globally - Dermatology Times, accessed April 30, 2025, https://www.dermatologytimes.com/view/christophe-piketty-md-phd-nemolizumab-s-unique-mechanism-of-action-and-next-steps-globally
21. IL-31 and Atopic Dermatitis | NEMLUVIO® (nemolizumab-ilto), accessed April 30, 2025, https://www.nemluviohcp.com/atopic-dermatitis/il-31-in-ad
22. Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis | National Eczema Association, accessed April 30, 2025, https://nationaleczema.org/blog/press-release-galderma-nemolizumab-moderate-to-severe-atopic-dermatitis/
23. Interleukin-31 as a Clinical Target for Pruritus Treatment - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7906974/
24. Galderma @ EADV 2023: phase III trials demonstrate nemolizumab's efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis, accessed April 30, 2025, https://www.galderma.com/news/galderma-eadv-2023-phase-iii-trials-demonstrate-nemolizumabs-efficacy-and-rapid-onset-action
25. Galderma's IL-31 Blocker Nemolizumab Wows in PN - - PracticalDermatology, accessed April 30, 2025, https://practicaldermatology.com/news/galdermas-il-31-blocker-nemolizumab-wows-in-pn/2461619/
26. Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab ..., accessed April 30, 2025, https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-adult-patients-living-prurigo
27. What diseases does Nemolizumab treat? - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/article/what-diseases-does-nemolizumab-treat
28. Galderma's Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis, accessed April 30, 2025, https://www.galderma.com/news/galdermas-nemluvior-nemolizumab-approved-european-union-moderate-severe-atopic-dermatitis-and
29. Nemolizumab - Chugai Pharmaceutical - AdisInsight - Springer, accessed April 30, 2025, https://adisinsight.springer.com/drugs/800036524
30. Mar 28,2022 | Maruho Obtained Regulatory Approval for Mitchga ..., accessed April 30, 2025, https://www.chugai-pharm.co.jp/english/news/detail/20220328160001_908.html
31. Galderma Receives U.S. FDA Approval for Nemluvio ..., accessed April 30, 2025, https://investors.galderma.com/news-releases/news-release-details/galderma-receives-us-fda-approval-nemluvior-nemolizumab-patients/
32. Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis, accessed April 30, 2025, https://www.galderma.com/news/galderma-receives-us-fda-approval-nemluvior-nemolizumab-patients-moderate-severe-atopic
33. Nemolizumab: First Approval - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/35834124/
34. NEMLUVIO® for Prurigo Nodularis and Atopic Dermatitis, accessed April 30, 2025, https://www.nemluvio.com/
35. Nemluvio (nemolizumab) FDA Approval History - Drugs.com, accessed April 30, 2025, https://www.drugs.com/history/nemluvio.html
36. FDA approves nemolizumab to treat atopic dermatitis in patients 12 years and up, accessed April 30, 2025, https://www.contemporarypediatrics.com/view/fda-approves-nemolizumab-to-treat-atopic-dermatitis-in-patients-12-years-and-up
37. Galderma's Nemluvio® (nemolizumab) granted marketing authorization in the United Kingdom and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis, accessed April 30, 2025, https://www.galderma.com/news/galdermas-nemluvior-nemolizumab-granted-marketing-authorization-united-kingdom-and-0
38. Galderma's Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis - Business Wire, accessed April 30, 2025, https://www.businesswire.com/news/home/20250217972666/en/Galdermas-Nemluvio-Nemolizumab-Granted-Marketing-Authorization-in-the-United-Kingdom-and-Switzerland-for-Moderate-to-Severe-Atopic-Dermatitis-and-Prurigo-Nodularis
39. CHMP positive for Nemluvio (nemolizumab) for the treatment of both atopic dermatitis and prurigo nodularis - Galderma - Medical Update Online, accessed April 30, 2025, https://medicalupdateonline.com/2025/01/chmp-positive-for-nemluvio-nemolizumab-for-the-treatment-of-both-atopic-dermatitis-and-prurigo-nodularis-galderma/
40. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials | News | CHUGAI PHARMACEUTICAL CO., LTD., accessed April 30, 2025, https://www.chugai-pharm.co.jp/english/news/detail/20240326170000_1061.html
41. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/story/5840301
42. Maruho Acquires Manufacturing and Marketing Approval in Japan for "Mitchga Subcutaneous Injection 30mg Vials", an Antibody Treatment for Pruritus Associated with Atopic Dermatitis (Pediatric) and Prurigo Nodularis | Information, accessed April 30, 2025, https://www.maruho.co.jp/english/information/20240326.html
43. Maruho Launches "Mitchga Subcutaneous Injection 30mg Vials", an Antibody Treatment for Pruritus Associated with Atopic Dermatitis (Pediatric) and Prurigo Nodularis in Japan | Information, accessed April 30, 2025, https://www.maruho.co.jp/english/information/20240611.html
44. Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market | News, accessed April 30, 2025, https://www.chugai-pharm.co.jp/english/news/detail/20160928150000_121.html
45. Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market - FirstWord Pharma, accessed April 30, 2025, https://firstwordpharma.com/story/4236544
46. Feb 15,2024 | Galderma Announces Updates on Nemolizumab Development | News | CHUGAI PHARMACEUTICAL CO., LTD., accessed April 30, 2025, https://www.chugai-pharm.co.jp/english/news/detail/20240215113000_1048.html
47. Dec 09,2019 | Chugai's Nemolizumab Receives FDA Breakthrough Therapy Designation for the Treatment of Pruritus Associated with Prurigo Nodularis | News, accessed April 30, 2025, https://www.chugai-pharm.co.jp/english/news/detail/20191209180000_676.html
48. Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis, accessed April 30, 2025, https://www.galderma.com/news/galderma-investigational-therapy-nemolizumab-granted-fda-breakthrough-therapy-designation
49. nemolizumab (Nemluvio®) - EOCCO, accessed April 30, 2025, https://www.eocco.com/-/media/EOCCO/PDFs/Formulary/EOCCO-Nemolizumab-Nemluvio-Policy.pdf
50. EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab's Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations | Business Wire, accessed April 30, 2025, https://www.businesswire.com/news/home/20240924578710/en/EADV-2024-Late-Breaking-News-Sessions-New-Galderma-Data-Demonstrating-Nemolizumab%E2%80%99s-Long-term-Efficacy-and-Safety-in-Atopic-Dermatitis-and-Durability-in-Prurigo-Nodularis-to-Be-Shared-During-Three-Oral-Presentations
51. Nemolizumab in Moderate-to-Severe Atopic Dermatitis: Long-Term Safety and Efficacy and New Biomarker Insights - EMJ, accessed April 30, 2025, https://www.emjreviews.com/dermatology/symposium/nemolizumab-in-moderate-to-severe-atopic-dermatitis-long-term-safety-and-efficacy-and-new-biomarker-insights-s030125/
52. Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis, accessed April 30, 2025, https://www.galderma.com/news/galderma-aad-2024-new-data-demonstrate-long-term-efficacy-nemolizumab-prurigo-nodularis-and
53. Nemolizumab improves signs, symptoms of atopic dermatitis up to 56 weeks - Healio, accessed April 30, 2025, https://www.healio.com/news/dermatology/20240930/nemolizumab-improves-signs-symptoms-of-atopic-dermatitis-up-to-56-weeks
54. Nemolizumab Humanized Recombinant Monoclonal Antibody (MA5-42056), accessed April 30, 2025, https://www.thermofisher.com/antibody/product/Nemolizumab-Humanized-Antibody-Recombinant-Monoclonal/MA5-42056
55. Nemolizumab Granted FDA Approval For Adults Living With Prurigo Nodularis, accessed April 30, 2025, https://www.pharmacytimes.com/view/nemolizumab-granted-fda-approval-for-adults-living-with-prurigo-nodularis
56. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39067461/
57. Efficacy and Safety of Nemolizumab in Patients With Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed Central, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11894857/
58. Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial | Request PDF - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/386178226_Efficacy_and_Safety_of_Nemolizumab_in_Patients_With_Moderate_to_Severe_Prurigo_Nodularis_The_OLYMPIA_1_Randomized_Clinical_Phase_3_Trial
59. Drug Trials Snapshots: NEMLUVIO - FDA, accessed April 30, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nemluvio
60. FDA approves Nemluvio for treatment of prurigo nodularis - Healio, accessed April 30, 2025, https://www.healio.com/news/dermatology/20240813/fda-approves-nemluvio-for-treatment-of-prurigo-nodularis
61. Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39602139/
62. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/35766128/
63. CLINICAL STUDY PROTOCOL - ClinicalTrials.gov, accessed April 30, 2025, https://cdn.clinicaltrials.gov/large-docs/43/NCT03985943/Prot_000.pdf
64. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/31449914/
65. ARCADIA: Nemolizumab Achieves Significant Itch Reduction by Day 2 of Treatment, accessed April 30, 2025, https://www.hcplive.com/view/arcadia-nemolizumab-achieves-significant-itch-reduction-by-day-2-of-treatment
66. Nemolizumab Completed Phase 2 Trials for Atopic Dermatitis Treatment | DrugBank Online, accessed April 30, 2025, https://go.drugbank.com/drugs/DB15252/clinical_trials?conditions=DBCOND0028414&phase=2&purpose=treatment&status=completed
67. Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/35088348/
68. Nemolizumab Completed Phase 2 Trials for Atopic Dermatitis Basic Science - DrugBank, accessed April 30, 2025, https://go.drugbank.com/drugs/DB15252/clinical_trials?conditions=DBCOND0028414&phase=2&purpose=basic_science&status=completed
69. Moderate-to-severe Atopic Dermatitis Recruiting Phase 2 Trials for Nemolizumab (DB15252) | DrugBank Online, accessed April 30, 2025, https://go.drugbank.com/indications/DBCOND0088001/clinical_trials/DB15252?phase=2&status=recruiting
70. EU Clinical Trials Register, accessed April 30, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000448-23/PL
71. Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study | British Journal of Dermatology | Oxford Academic, accessed April 30, 2025, https://academic.oup.com/bjd/advance-article/doi/10.1093/bjd/ljaf045/8088394
72. Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study | British Journal of Dermatology | Oxford Academic, accessed April 30, 2025, https://academic.oup.com/bjd/article/190/1/20/7233858
73. Cutaneous Adverse Events Following Nemolizumab Administration: A Review - MDPI, accessed April 30, 2025, https://www.mdpi.com/2077-0383/14/9/3026
74. Systemic Sclerosis (SSc) Completed Phase 2 Trials for Nemolizumab (DB15252), accessed April 30, 2025, https://go.drugbank.com/indications/DBCOND0047798/clinical_trials/DB15252?phase=2&status=completed